Torasemide

Drug Profile

Torasemide

Alternative Names: BM 02015; C 3534; C 3535; Demadex; Dilutol; GJ 1090; Isodiur; JDL 464; Luprac; Sutril; Toradiur; Torem; Toresmide; Torrem R; Torsemide; Trasemide; Unat; Zemide

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Christiaens
  • Developer Christiaens; Laboratorios Novag; Mitsubishi Tanabe Pharma Corporation; Roche; Toyama Chemical
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
  • Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension; Kidney disorders; Liver disorders

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 24 Mar 2011 Generic equivalent approved in USA for oedema associated with Congestive heart failure, Renal disease or Hepatic disease
  • 15 Aug 2008 Meda acquires Torasemide for Heart failure from Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top